Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Blue Sky MD vs FuturHealth

Blue Sky MD
Graded #157

Higher grade

vs+2.1000000000000085
FuturHealth
Graded #215

Lower grade

The verdict

Blue Sky MD takes it — 67.7/100 to 65.6/100.

Blue Sky MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Blue Sky MD is a LegitScript-certified medical weight-loss practice founded in 2008 with seven North Carolina clinics and telehealth visits available.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBlue Sky MD +5
65
60
Dose & formulationFuturHealth +17
64
81
Clinical oversightBlue Sky MD +20
87
67
Labs & monitoringBlue Sky MD +1
62
61
FulfillmentBlue Sky MD +1
63
62
Contract termsEven
55
55
Blue Sky MD · left barFuturHealth · right bar

The numbers

MetricBlue Sky MDFuturHealth
WeighScore67.7/10065.6/100
GradeCC
Scorecard rank#157#215
Semaglutide$160/mo (starting dose, compounded)$199/mo (compounded)
Tirzepatide$240/mo (starting dose, compounded)Not disclosed
Coverage1 stateCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
Blue Sky MD

Graded #157 · C

Strengths

  • LegitScript certified and physician-led since 2008; one of the most established GLP-1 practices in the Southeast
  • Compounded semaglutide from $40/week (~$160/month) and tirzepatide from $60/week (~$240/month) — well below brand-name cost
  • Comprehensive program includes 1-on-1 wellness coaching, nutrition plans, hormone analysis, and a proprietary mobile app
  • Medication shipped directly to patients’ homes within 3–5 business days; telehealth visits available
  • Insurance accepted in many cases; affordable self-pay options for uninsured patients

Where it loses points

  • Geographic reach unclear — physical clinics in NC only; telehealth states beyond NC unconfirmed despite 'from virtually anywhere' claim
  • Pricing quoted per-week ($40 sema / $60 tirz) rather than per-month; higher-dose pricing not disclosed
  • Must enroll in full medical weight-loss program to access GLP-1 medications — medication-only Rx not offered
  • No explicit lab testing protocol published; online FAQ does not confirm labs are included
  • Small regional provider vs. national platforms; limited provider footprint outside North Carolina
FuturHealth

Graded #215 · C

Strengths

  • LegitScript Certified and HITRUST Certified
  • Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
  • Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
  • Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths

Where it loses points

  • Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
  • BBB complaints describe recurring charges without medication received — confirm cancellation flow first
  • Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
  • Pricing not shown until after the qualification questionnaire or portal login
  • Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard